Catalog No.: PC-25932Not For Human Use, Lab Use Only.
Buloxibutid (C21) is an orally available, selective, high-affinity angiotensin II type 2 receptor (AT2R) agonist with Ki of 0.4 nM, >10,000-fold selective over AT1R.
Buloxibutid (C21) is an orally available, selective, high-affinity angiotensin II type 2 receptor (AT2R) agonist with Ki of 0.4 nM, >10,000-fold selective over AT1R. Buloxibutid induces outgrowth of neurite cells, stimulates p42/p44(mapk), enhances in vivo duodenal alkaline secretion in Sprague-Dawley rats, and lowers the mean arterial blood pressure in anesthetized, spontaneously hypertensive rats. Buloxibutid exerts a similar biological response as the endogenous peptide angiotensin II after selective activation of the AT(2) receptor. Buloxibutid reduced vascular remodeling (reduced endothelial proliferation and thickening of the vascular wall) in vesselsof rat Sugen-hypoxia PH model. Buloxibutid (C21) significantly inhibited AML progression and enhanced the efficacy of chemotherapy, particularly in relapsed AML models.
